Biomea fusion

Biomea Fusion is a biopharmaceutical company focused on developing covalent small molecule therapies for genetically defined cancers and metabolic diseases. The company leverages its proprietary FUSION™ System to design targeted, irreversible inhibitors that offer potential advantages in potency, selectivity, and dosing frequency compared to traditional therapies. Biomea Fusion primarily targets healthcare providers, researchers, and patients involved in oncology and precision medicine treatment approaches.